Beam Therapeutics (BEAM) Gains from Sales and Divestitures: 2020-2025
Historic Gains from Sales and Divestitures for Beam Therapeutics (BEAM) over the last 6 years, with Sep 2025 value amounting to $783,939.
- Beam Therapeutics' Gains from Sales and Divestitures rose 36.25% to $783,939 in Q3 2025 from the same period last year, while for Sep 2025 it was $783,939, marking a year-over-year increase of 36.25%. This contributed to the annual value of $1.3 million for FY2024, which is 177.31% up from last year.
- Per Beam Therapeutics' latest filing, its Gains from Sales and Divestitures stood at $783,939 for Q3 2025, which was up 13.89% from $688,359 recorded in Q2 2025.
- Over the past 5 years, Beam Therapeutics' Gains from Sales and Divestitures peaked at $1.3 million during Q4 2024, and registered a low of $283,186 during Q1 2022.
- Over the past 3 years, Beam Therapeutics' median Gains from Sales and Divestitures value was $492,619 (recorded in 2024), while the average stood at $580,852.
- Per our database at Business Quant, Beam Therapeutics' Gains from Sales and Divestitures crashed by 58.44% in 2022 and then skyrocketed by 177.31% in 2024.
- Quarterly analysis of 5 years shows Beam Therapeutics' Gains from Sales and Divestitures stood at $1.0 million in 2021, then slumped by 58.44% to $424,303 in 2022, then grew by 10.66% to $469,531 in 2023, then soared by 177.31% to $1.3 million in 2024, then spiked by 36.25% to $783,939 in 2025.
- Its Gains from Sales and Divestitures was $783,939 in Q3 2025, compared to $688,359 in Q2 2025 and $607,196 in Q1 2025.